Added 14,630 shares of AbbVie, an estimated $3.39 million trade based on average pricing for Q3 2025
Transaction represents 2.2% of reportable AUM as of September 30, 2025
Post-trade, the firm holds 14,630 shares valued at $3.39 million as of September 30, 2025
The new position places AbbVie outside the fund’s top five holdings
St. Louis Financial Planners Asset Management, LLC initiated a new stake in AbbVie (NYSE:ABBV), acquiring 14,630 shares for an estimated $3.39 million in Q3 2025.
According to a Securities and Exchange Commission (SEC) filing dated October 02, 2025, St. Louis Financial Planners Asset Management, LLC disclosed a new position in AbbVie(NYSE:ABBV). The firm acquired 14,630 shares, bringing its quarter-end holding to $3.39 million. The position accounted for 2.1842% of the fund’s $155,093,822 in reportable U.S. equity assets across 37 positions.
This new position represents 2.2% of the fund’s 13F assets as of 2025-09-30
Top holdings after the filing:
As of October 1, 2025, AbbVie shares were priced at $244.38, up 24.08% over the past year and outperforming the S&P 500 by 11.71 percentage points
| Metric | Value |
|---|---|
| Revenue (TTM) | $58.33 billion |
| Net Income (TTM) | $3.77 billion |
| Dividend Yield | 2.72% |
| Price (as of market close 2025-10-01) | $244.38 |
AbbVie generates revenue primarily through the development, manufacturing, and sale of branded pharmaceuticals, including key products such as HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, and BOTOX Therapeutic.
The company operates a research-driven business model, focusing on innovation and the expansion of its drug portfolio across multiple therapeutic areas.
AbbVie serves a global customer base, including healthcare providers, hospitals, and government agencies, with a focus on advanced therapies for autoimmune diseases, oncology, and specialty care.
AbbVie discovers, develops, manufactures, and sells pharmaceuticals worldwide, including products for autoimmune diseases, oncology, and other conditions. Its diversified portfolio and commitment to research support its competitive position in the healthcare sector.
AbbVie is one of the top pharmaceutical companies on the market right now, despite its relatively recent loss of patent for Humira, which was a blockbuster drug for the company. Despite this, its dividend remains strong and its drug pipeline robust. Several new drugs are in the works for fields like immunology, oncology, and aesthetics.
Since its acquisition of Allergan, maker of Botox, AbbVie has been burdened with a higher debt load than usual, but equally high cash flows have kept balance sheets healthy. However, a dependence on a few successful drugs does create serious risk should regulation or pricing pressures become a more significant factor in the near term. Higher interest rates could also become a problem, should the company need to refinance the debt it acquired in 2019 with the purchase of Allergan.
Even so, AbbVie is still a solid Wall Street Buy recommendation, with 5 Strong Buys and 13 Buys for October, as well as 9 Hold recommendations. It continues to beat on analysis estimated EPS this year, showing that it can, in fact, pivot despite the loss of a major income stream.
Stake: The ownership or investment a firm holds in a particular company or asset.
Reportable AUM: Assets under management that must be disclosed in regulatory filings, such as the SEC’s 13F report.
13F assets: U.S. equity securities managed by institutional investment managers, reported quarterly to the SEC on Form 13F.
Top holdings: The largest investments in a fund’s portfolio, typically ranked by market value.
Dividend yield: Annual dividends paid by a company as a percentage of its current share price.
Outperforming: Achieving a higher return than a benchmark index or comparable investment.
TTM: The 12-month period ending with the most recent quarterly report.
Branded pharmaceuticals: Prescription drugs sold under a trademarked brand name, as opposed to generic versions.
Autoimmune diseases: Medical conditions where the immune system mistakenly attacks the body’s own tissues.
Oncology: The branch of medicine focused on the diagnosis and treatment of cancer.
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,063%* — a market-crushing outperformance compared to 191% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of September 29, 2025
Kristi Waterworth has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Palantir Technologies. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
